124 Chapter 5 52. Slot RER, Kester MI, Van Harten AC, Jongbloed W, Bouwman FH, Teunissen CE, et al. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly. Neurobiology of aging. 2019;79:101-9. 53. van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nature Reviews Neuroscience. 2020;21(1):21-35. 54. Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer’s disease. Nature neuroscience. 2020;23(3):311-22. 55. Stocker H, Möllers T, Perna L, Brenner H. The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores. Translational psychiatry. 2018;8(1):166. 56. Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer’s disease. Brain: a journal of neurology. 2015;138(12):3673-84. 57. Zhang Q, Sidorenko J, Couvy-Duchesne B, Marioni RE, Wright MJ, Goate AM, et al. Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture. Nature communications. 2020;11(1):4799.